IN.PACT Admiral Drug-Coated Balloon From Medtronic Outperforms Standard Angioplasty in Study

Interventional Treatment of Lower-Extremity Peripheral Arterial Disease With Novel Medical Device Shows Positive Results in IN.PACT SFA Trial LONDON –– April 5, 2014 ––Patients with peripheral artery disease in the upper leg experienced significantly better outcomes at 12 months after treatment with the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. than with standard balloon angioplasty, according to a landmark clinical study reported on today for the first time. The IN.PACT SFA Trial enrolled 331 subjects at 57 sites across Europe and the United States. All study subjects were randomized to treatment with the drug-coated balloon (DCB) or percutaneous transluminal angioplasty (PTA). On the key endpoints: · The clinically driven target lesion revascularization (CD-TLR) rates at 12 months were 2.4 percent for the DCB group and 20.6 percent for the PTA group (p